Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug;15(5):751-753.
doi: 10.1007/s11739-020-02331-1. Epub 2020 Apr 15.

Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients

Sophie Testa  1 , Oriana Paoletti  2 , Matteo Giorgi-Pierfranceschi  3 , Angelo Pan  4
Affiliations

Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients

Sophie Testa et al. Intern Emerg Med. 2020 Aug.

Abstract

The development of COVID-19 syndrome in anticoagulated patients, and especially their admission to intensive-care units with acute severe respiratory syndrome (SARS-CoV-2), expose them to specific problems related to their therapy, in addition to those associated with the acute viral infection. Patients on VKA hospitalized with SARS-CoV-2 show high instability of PT INR due to the variability of vitamin K metabolism, diet, fasting, co-medications, liver impairment, and heart failure. Patients on DOAC are exposed to under/over treatment caused by significant pharmacological interferences. In consideration of the pharmacological characteristics of oral anticoagulant drugs, the multiple pharmacological interactions due to the treatment of acute disease and the possible necessity of mechanical ventilation with hospitalization in intensive-care units, we suggest replacing oral anticoagulant therapies (VKA and DOAC) with parenteral heparin to avoid the risk of over/under treatment.

Keywords: COVID-19; DOAC; LMWH; SARS-CoV-2; VKA.

PubMed Disclaimer

Conflict of interest statement

Authors received no specific foundings for this work and declare no conflict of interest.

Comment in

References

    1. Phelan AL, Katz R, Gostin LO. The novel coronavirus originating in Wuhan, China: challenges for global health governance. JAMA. 2020 doi: 10.1001/jama.2020.1097. - DOI - PubMed
    1. World Health Organization (WHO) (2020) Coronavirus disease 2019 (COVID-19). Situation Report—51. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situatio...
    1. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141:e44S–88S. doi: 10.1378/chest.11-2292. - DOI - PMC - PubMed
    1. Prisco D, Ageno W, Becattini C, D'Angelo A, Davì G, De Cristofaro R, Dentali F, Di Minno G, Falanga A, Gussoni G, Masotti L, Palareti G, Pignatelli P, Santi RM, Santilli F, Silingardi M, Tufano A, Violi F, SIMI (Italian Society of Internal Medicine) FADOI (Federation of Associations of Hospital Doctors on Internal Medicine) SISET (Italian Society for the Study of Haemostasis and Thrombosis) Italian intersociety consensus on DOAC use in internal medicine. Intern Emerg Med. 2017;12(3):387–406. doi: 10.1007/s11739-017-1628-6. - DOI - PubMed
    1. Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH. Antithrombotic and thrombolytic therapy for valvular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e576S–e600S. doi: 10.1378/chest.11-2305. - DOI - PMC - PubMed